Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals

January 19, 2017

Speaking at the 2017 Biotech Showcase™ in San Francisco, Grünenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time

Previous Video
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 20...

Next Video
Digital Medicine Showcase 2017: State of the Digital Medicine Industry
Digital Medicine Showcase 2017: State of the Digital Medicine Industry

Tools that will usher in a new age of healthcare are changing the game by creating more effective R&D proce...